Schmittel A - Search Results

1

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C. Nagorsen D, et al. Among authors: schmittel a. Cancer Res. 2000 Sep 1;60(17):4850-4. Cancer Res. 2000. PMID: 10987297

2

Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides.

Scheibenbogen C, Nagorsen D, Seliger B, Schmittel A, Letsch A, Bauer S, Max N, Bock M, Atkins D, Thiel E, Keilholz U. Scheibenbogen C, et al. Among authors: schmittel a. Int J Cancer. 2002 May 20;99(3):403-8. doi: 10.1002/ijc.10328. Int J Cancer. 2002. PMID: 11992409

3

Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients.

Nagorsen D, Scheibenbogen C, Schaller G, Leigh B, Schmittel A, Letsch A, Thiel E, Keilholz U. Nagorsen D, et al. Among authors: schmittel a. Int J Cancer. 2003 Jun 10;105(2):221-5. doi: 10.1002/ijc.11052. Int J Cancer. 2003. PMID: 12673683

4

Rational peptide-based tumour vaccine development and T cell monitoring.

Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U. Scheibenbogen C, et al. Among authors: schmittel a. Semin Cancer Biol. 2003 Dec;13(6):423-9. doi: 10.1016/j.semcancer.2003.09.006. Semin Cancer Biol. 2003. PMID: 15001161 Review.

5

Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients.

Letsch A, Keilholz U, Fluck M, Nagorsen D, Asemissen AM, Schmittel A, Thiel E, Scheibenbogen C. Letsch A, et al. Among authors: schmittel a. Int J Cancer. 2005 May 10;114(6):936-41. doi: 10.1002/ijc.20819. Int J Cancer. 2005. PMID: 15645483 Clinical Trial.

6

Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).

Asemissen AM, Scheibenbogen C, Letsch A, Hellstrand K, Thorén F, Gehlsen K, Schmittel A, Thiel E, Keilholz U. Asemissen AM, et al. Among authors: schmittel a. Clin Cancer Res. 2005 Jan 1;11(1):290-7. Clin Cancer Res. 2005. PMID: 15671558 Clinical Trial.

7

Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood.

Schmittel A, Keilholz U, Scheibenbogen C. Schmittel A, et al. J Immunol Methods. 1997 Dec 29;210(2):167-74. doi: 10.1016/s0022-1759(97)00184-1. J Immunol Methods. 1997. PMID: 9520299

8

Induction of tyrosinase-reactive T cells by treatment with dacarbazine, cisplatin, interferon-alpha +/- interleukin-2 in patients with metastatic melanoma.

Schmittel A, Keilholz U, Max R, Thiel E, Scheibenbogen C. Schmittel A, et al. Int J Cancer. 1999 Jan 5;80(1):39-43. doi: 10.1002/(sici)1097-0215(19990105)80:1<39::aid-ijc8>3.0.co;2-y. Int J Cancer. 1999. PMID: 9935227 Clinical Trial.

9

Quantification of tumor-specific T lymphocytes with the ELISPOT assay.

Schmittel A, Keilholz U, Thiel E, Scheibenbogen C. Schmittel A, et al. J Immunother. 2000 May-Jun;23(3):289-95. doi: 10.1097/00002371-200005000-00001. J Immunother. 2000. PMID: 10838657 Review.

10

High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma.

Letsch A, Keilholz U, Schadendorf D, Nagorsen D, Schmittel A, Thiel E, Scheibenbogen C. Letsch A, et al. Among authors: schmittel a. Int J Cancer. 2000 Sep 1;87(5):659-64. Int J Cancer. 2000. PMID: 10925359

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Search Page

Filters